Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 517

Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK

Dr Pickering speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the multicentre single-arm phase II VinCaP trial, looking into the use of of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis.

The trial of 25 patients delivered 4 cycles of chemotherapy.

The trial exceeded it's primary endpoint (of 7 patients) with 10 patients showing stable disease or objective response.

The toxicities reported were neutropenia, anaemia and sepsis. 

Overall it was a successful study since some patients who were previously deemed unsuitable for combination chemotherapy were able to receive this form of chemotherapy.

Due to the rarity of penis cancer, there have only been small studies to date, so this is an emerging field.

To get a large enough patient group for a randomised trial, we would need to be looking on a global level. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation